Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Applied nutritional investigation

Serum zinc and copper in people with COVID-19 and zinc supplementation in parenteral nutrition

Francisco Arrieta M.D., Ph.D., a,b Victoria Martinez-Vaello M.D., a Nuria Bengoa M.D., a Lucía Jiménez-Mendiguchia M.D., c Marta Rosillo M.D., Ph.D., c Angélica de Pablo M.D., d Cristina Voguel M.D., d Hilario Martinez-Barros M.D., e Rosario Pintor M.D., e Amaya Belanger-Quintana M.D., Ph.D., f Raquel Mateo M.D., a Angel Candela M.D., d José I. Botella-Carretero M.D., Ph.D., M.B.A., a,b,*

a Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Madrid, Spain
b Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y Nutrición (CIBERobn) & IRyCIS, Madrid, Spain
c Department of Biochemistry, Hospital Universitario Ramón y Cajal, Madrid, Spain
d Department of Anesthesiology, Hospital Universitario Ramón y Cajal, Madrid, Spain
e Department of Pharmacy, Hospital Universitario Ramón y Cajal, Madrid, Spain
f Department of Pediatrics, Hospital Universitario Ramón y Cajal, Madrid, Spain

ARTICLE INFO

Article History:
Received 23 March 2021
Received in revised form 10 June 2021
Accepted 24 August 2021

Keywords:
COVID-19
Zinc
Copper
Parenteral nutrition
Critical care

ABSTRACT

Objectives: Zinc and copper are important to protect cells from oxidative stress and to enhance immunity. An association between low zinc levels and the severity of acute respiratory distress syndrome has been shown for people with COVID-19. We aimed to study serum zinc and copper concentrations in people with severe COVID-19 and zinc supplementation in parenteral nutrition (PN).

Methods: Thirty-five people with COVID-19 in need of PN were studied in a retrospective design. Serum samples were collected at three time points: at the start of PN, between 3 and 7 d after, and at the end of PN.

Results: Participants were on PN for a mean of 14 d, with a mean (±SD) daily supplemental zinc of 14.8 ± 3.7 mg/d. Serum zinc increased during PN administration from 98.8 ± 22.8 to 114.1 ± 23.3 mg/dL (Wilks’ λ = 0.751, F = 5.459, P = 0.009). Conversely, serum copper did not vary from baseline (107.9 ± 34.2 mg/dL) to the end of the study (104.5 ± 37.4 mg/dL, Wilks’ λ = 0.919, F = 1.453, P = 0.248). Serum zinc within the first week after starting PN and at the end of PN inversely correlated with total hospital stay (r = −0.413, P = 0.014, and r = −0.386, P = 0.022, respectively). Participants in critical condition presented lower serum copper (z = 2.615, P = 0.007). Mortality was not associated with supplemental zinc or with serum zinc or copper concentrations at any time of the study (P > 0.1 for all analyses).

Conclusions: Serum zinc concentrations during PN support were inversely associated with length of hospital stay but not with mortality. Serum copper concentrations were lower in participants in critical condition but not associated with prognosis.

© 2021 Elsevier Inc. All rights reserved.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the coronavirus disease 2019 (COVID-19) pandemic, which has affected more than 200 million individuals and has been the cause of more than four million deaths worldwide as of this writing [1]. An important proportion of people with COVID-19 may present severe pneumonia requiring hospital admission, some to an intensive care unit (ICU). In these people, an excessive release of inflammatory cytokines, activation of procoagulating factors, and increased oxidative stress may occur [2]. The disease can then progress to acute...
respiratory distress syndrome and other multiple organ failures such as acute cardiac, liver, or kidney injury [3,4]. In this situation, artificial nutrition may be needed to avoid further malnutrition, either as parenteral nutrition (PN) or as enteral nutrition [5,6].

Apart from macronutrients, several micronutrients are usual components of artificial nutrition, based on average requirements. Among these, some trace elements such as zinc and copper are important to protect cells from oxidative stress, especially in patients in critical care [7]. People who are critically ill develop severe stress and a state that may raise the utilization and metabolic replacement of some of these trace elements, especially zinc, depleting their body reserves [8]. In addition, enzymes dependent on trace elements are of great importance in the antioxidant defense mechanisms to protect cells from reactive oxygen species [9]. Accordingly, low serum levels of zinc and copper have been observed at ICU admission, and those with higher serum concentrations have shown significantly lower mortality [10,11].

Recently, an association between low zinc levels and the severity of acute respiratory distress syndrome has been shown for people with severe COVID-19 [12]. Therefore, given this previous knowledge, we aimed to study serum zinc and copper concentrations in people with severe COVID-19 and zinc supplementation in PN, as well as their associations with inflammatory markers and prognosis.

Materials and methods

Participants

Thirty-five COVID-19 patients in need of PN were studied in a retrospective design. Inclusion criteria were confirmation of COVID-19 by the presence of SARS-CoV-2 in respiratory specimens by real-time polymerase chain reaction in pharyngeal swabs, severe pneumonia requiring high-flow oxygen, the need for artificial nutrition in the form of PN, and available serum samples for zinc and copper measurements. The latter were collected at three time points: at the start of PN, between 3 and 7 d after, and at the end of PN. All participants received our standard treatment protocol for COVID-19, including glucocorticoids, low-molecular-weight heparin, and tocilizumab if indicated.

The study protocol was approved by the institutional ethics committee of our center (study code 147/20) and performed according to the Declaration of Helsinki. Written or verbal informed consent was obtained from all participants.

Artificial nutrition therapy

The composition of artificial nutrition administered to the participants was recorded. PN was delivered through a central line as soon as the participant was hemodynamically stable. Individualized formulae were prepared by the hospital pharmacy, and whenever possible, commercial “ready to use” bags were initially used (Olimel N9, Baxter Ltd., Deerfield, IL, USA). Some participants were started on peripheral PN (Peri- limel N9, Baxter Ltd., or Isoplasmal, Braun Medical Inc., Melsungen, Germany).

We aimed at 20 to 25 kcal/kg/d, with a proportion of 3 to 6 g/kg/d for glucose, 1.0 g/kg for amino acids, and <1 g/kg/d for lipids, with 7 to 10 g/d of essential fatty acids. Vitamins (Cernevit, Baxter Ltd.) and trace elements (Supliven, Fresenius Baxter Ltd., Deerfield, IL, USA) were added to PN. The latter contains 1.05 mg/mL of zinc chloride. Supplemental zinc was also added to PN bags when needed in the form of zinc sulfate (10 mg in 10-mL vials; Oligozinc, Fresenius Kabi, Bad Homburg, Germany) to maintain serum zinc in the normal range. Mean daily zinc doses were calculated during PN from all parenteral sources. For those participants with stays >7 d and whenever possible, enteral nutrition was started with a standard fiber-free formulation, and PN gradually tapered as enteral nutrition was tolerated and increased. After PN withdrawal, parenteral zinc supplementation stopped. Therefore, the analysis was restricted to the period of PN administration.

Analytical assays

Serum biochemical variables were measured with an Architect c16000/i2000 analyzer (Abbott Diagnostics, City, UK). Serum copper was analyzed by atomic absorption spectrophotometry (AAnalyst 800, Perkin Elmer, City, CA, USA). Serum zinc was analyzed by a colorimetric method (Sentinel Diagnostics, Milano, Italy). The normal ranges were 60 to 150 µg/dL for zinc and 75 to 150 µg/dL for copper. Immunoanalysis was used to measure C-reactive protein, procalcitonin (Abbott Diagnostics, City, ST, US) and D dimer (Siemens, City, Germany), and interleukin-6 and interleukin-12 by enzyme-linked immunosorbent assay (Innogen, City, CA, USA). The intra- and interassay coefficients of variation were below 10%.

Statistical analysis

Sample size was calculated with the online calculator GRANMO 7.12 (https://www.imuem.es/ofertadeservicios/software-public/granmo/index.html). To find a mean difference of 15 µg/dL in circulating zinc and copper between baseline levels and at the end of follow-up, with an SD of 25 µg/dL, a minimum sample size of 22 participants was needed for a bilateral contrast, with an α of 0.05, 1 – β of 0.20 and no expected losses. Results are expressed as mean ± SD unless otherwise stated. The Kolmogorov–Smirnov statistic was applied to continuous variables. Logarithmic or square-root transformations were used as needed to ensure normal distribution of the variables. To compare discontinuous variables, we used the χ² test or Fisher’s exact test as appropriate. Unpaired t tests or Mann–Whitney U tests were used to compare the central tendencies of the different groups, as appropriate. A general linear model repeated-measures test was used to analyze continuous variables measured several times during the study period. Bivariate correlation was used to study the association between two continuous variables, using Pearson’s or Spearman’s test, as appropriate. Analyses were performed using SPSS 18 (SPSS Inc., Chicago, IL, USA). We considered P <0.05 statistically significant.

Results

The baseline characteristics of the 35 participants are shown in Table 1. Most were male, less than half had hypertension, and less than a third had obesity or previous type 2 diabetes mellitus. Twenty-seven participants were critical ones admitted to the ICU, and the other eight were in respiratory intermediate care. Participants were on total PN for a mean of 14 d, with a mean daily supplemental zinc of 14.8 ± 3.7 mg/d. Only one participant had zinc deficiency at baseline according to our hospital reference range.

At follow-up there was an increase in alanine aminotransferase, γ-glutamyl transpeptidase, and D dimer, whereas serum interleukin-6, interleukin-12, total proteins, and albumin remained stable (Table 2). Serum zinc concentrations increased during PN administration from 98.8 ± 22.8 to 114.1 ± 23.3 µg/dL (Wilks’ λ = 0.751, F = 5.459, P = 0.009; Fig. 1). Conversely, serum copper concentrations did not vary from baseline (107.9 ± 34.2 µg/dL) to the end of the study (104.5 ± 37.4 µg/dL, Wilks’ λ = 0.919, F = 1.453, P = 0.248; Fig. 1).

Serum zinc at baseline did not correlate with any prognostic variable. Conversely, serum zinc within the first week after starting PN and serum zinc at the end of PN were inversely correlated with total hospital stay (r = −0.413, P = 0.014, and r = −0.386, P = 0.022, respectively; Fig. 2). Mean daily supplemental zinc was inversely correlated with CURB-65, pneumonia severity score; ICU, intensive care unit; PN, parenteral nutrition.
Table 2
Biochemical and inflammatory variables throughout the study

| Variable            | Baseline | End of PN | P     |
|---------------------|----------|-----------|-------|
| Glycerina, mg/dL    | 139 ± 54 | 151 ± 68  | 0.105 |
| Creatinine, mg/dL   | 1.0 ± 0.5| 1.1 ± 0.5 | 0.647 |
| ALT, U/L            | 63 ± 50  | 87 ± 93   | 0.001 |
| AST, U/L            | 49 ± 35  | 50 ± 47   | 0.944 |
| GGT, U/L            | 109 ± 130| 228 ± 240| <0.001|
| Alkaline phosphatase, U/L | 96 ± 70 | 115 ± 78  | 0.086 |
| Total cholesterol, mg/dL | 173 ± 60 | 194 ± 65  | 0.074 |
| Triacylglycerol, mg/dL | 379 ± 261| 365 ± 252| 0.103 |
| Serum total proteins, g/L | 6.4 ± 1.1 | 6.4 ± 0.7 | 0.633 |
| Serum albumin, g/L  | 2.9 ± 0.5| 2.6 ± 0.6 | 0.482 |
| CRP, mg/L           | 172 ± 122| 92 ± 66   | 0.723 |
| Procalcitonin, ng/mL| 0.7 ± 1.8| 0.6 ± 2.5 | 0.724 |
| D dimer, μg/mL      | 5183 ± 11,270 | 7810 ± 14,514 | <0.001|
| IL-6, pg/mL         | 417 ± 922| 1029 ± 2374| 0.660 |
| IL-12, pg/mL        | 0.8 ± 1.6| 1.3 ± 1.2 | 0.863 |

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; GGT, γ-glutamyl transpeptidase; IL, interleukin; PN, parenteral nutrition. Data are mean ± SD.

Discussion
We have shown in the present study that supplementation of zinc in PN produced an increase in serum zinc concentrations in people with severe COVID-19 infection. Serum zinc concentrations during PN support were inversely associated with length of hospital stay but not with mortality. This association was observed in patients in both ICU and intermediate care. In addition, serum copper concentrations were lower in those in the ICU but were not associated with prognosis.

Zinc is a highly abundant element on Earth, and it is an essential micronutrient. After ingestion and absorption through the small intestine, it is bound predominantly to albumin as well as to other proteins, including prealbumin, α₂-macroglobulin, transferrin, ceruloplasmin, haptoglobin, immunoglobulins, and complements. Serum circulating zinc accounts for only 0.1% of total body stores [13]. There are two families of proteins responsible for the movement of zinc across membranes; zinc-importer proteins, which transport it into the cytosol, and zinc transporter family proteins, which transport it outside the cytosol [14]. Most of the body content of zinc is found in muscle and bone, but many other organs—such as the liver, intestine, kidney, skin, lung, brain, heart, and pancreas—also contain significant concentrations. Its role within the human body is extensive in reproduction, immune function, wound repair, and, on the microcellular level, activity of macrophages, neutrophils, natural killer cells, and complements [15].

Notably, major risk groups for COVID-19—older people, men more than women, people who are obese, and people with diabetes—are all at risk of zinc deficiency [16]. Further, people who are critically ill may have elevated utilization of zinc, depleting their body reserves [8] and compromising the antioxidant defense mechanisms that protect cells from reactive oxygen species [9]. The alteration of zinc metabolism is more pronounced in people who are septic than in people who are critically ill but not infected. Specifically, sepsis is associated with lower plasma zinc concentrations [17]. A previous study reports that low serum zinc was very common at the onset of acute respiratory failure in the ICU but had no predictive value for 30-d mortality, ICU length of stay, or time of invasive mechanical ventilation [18]. In another study with a pediatric population, plasma zinc was correlated with measures of inflammation on day 3 and was associated with the degree of multorgan failure in the ICU [19].

Therefore, zinc supplementation has been suggested as a novel strategy to influence severe COVID-19, as it may enhance the antiviral immune response [20,21]. Indeed, much evidence has accumulated over the past 50 y to demonstrate the antiviral activity of zinc against a variety of viruses and via numerous mechanisms [22]. Although the exact underlying mechanism of zinc-induced antiviral response is not well understood, it has been demonstrated that zinc has the potential to inhibit viral binding to the mucosal cells and eventual replication, possibly by generating antiviral interferon. In addition, it has been proposed that zinc may reduce expression of sirtuin 1-mediated cell-surface angiotensin-converting enzyme 2, the binding site for the SARS-CoV-2 spike protein [23].

Our results, although limited by the nature of a small retrospective study, show some interesting data on zinc supplementation in PN and the prognosis of people with severe COVID-19. Further, some of them are in agreement with recent reported data showing an association between low zinc levels and the severity of acute respiratory distress syndrome in people with severe COVID-19 [12]. The latter study included 269 people with severe COVID-19 admitted to an ICU, mostly men, with a mean age of 70 y and a median body mass index of 30 kg/m². The researchers measured serum zinc at admission and found an association of low zinc levels and severe acute respiratory distress syndrome even after adjusting for baseline variables [12]. Although we did not find an association between prognosis and baseline zinc concentrations, we identified only one participant with zinc deficiency, in contrast to the data reported in that previous study, which showed a 79.6% prevalence of low zinc levels. Our study has the advantage of serum zinc measurements at follow-up, and direct quantification of the parenteral zinc administered with PN. We were able to show a dynamic picture of serum zinc changes and an association of serum zinc levels after PN support with the length of hospital stay.

Copper is a component of the Cu/Zn superoxide dismutase and serves as a free radical scavenger [7]. In relatively small amounts, it is an essential cofactor of a broad array of molecules [24]. Common dietary sources of copper are meat, shellfish, seeds, legumes, nuts, whole grains, potatoes, and chocolate. After intestinal absorption, it circulates mainly bound to serum albumin and is carried to the liver. A small amount of copper is excreted in bile, and the rest binds to ceruloplasmin—a copper-dependent ferroxidase—and is released back into the bloodstream [25]. Increased serum copper concentrations during ICU care were associated with significantly lower mortality in a recent study [10]. Another previous study showed that copper supplementation produced significantly fewer 30-d infectious episodes and a significantly shorter length of stay in people with major burns, but a deep analysis showed that the results were associated not with copper levels but with the increased amount of supplemented selenium [26,27]. To our knowledge, there have been no reports of studies dealing with copper supplementation in people with COVID-19, although it has been recently proposed as an adjunct therapy in these patients from a theoretical point of view [28]. Ours, then, are novel data that show an association of lower serum copper concentrations with critical COVID-19 illness.

It has been suggested that the altered plasma concentrations of zinc, selenium, and copper in people with critical illness may be primarily due to the effects of the systemic inflammatory response and may not reliably indicate their status [29]. We did not measure zinc and copper in red blood cells, so this could be a limitation of the ICU setting.
Fig. 1. Serum concentrations of zinc and copper throughout the study. Squares represent mean serum concentrations, and error bars represent standard error of the mean. *P < 0.01. PN, parenteral nutrition.
In conclusion, serum zinc concentrations during PN support were inversely associated with length of hospital stay but not with mortality in people with severe COVID-19. In addition, serum copper concentrations were lower in participants in the ICU but were not associated
Fig. 3. Serum copper concentrations of participants in the intensive care unit (black bars) versus those in intermediate care (gray bars). Bars represent means and error bars represent standard error of the mean. * P < 0.05. PN, parenteral nutrition.

with prognosis. Therefore, from the clinical experience, prophylactic supplementation of PN with zinc could be considered in these patients. Future clinical trials are needed to unravel the role of zinc and copper supplementation in people with severe COVID-19.

References

[1] John Hopkins University of Medicine. Coronavirus resource center. Available at: https://coronavirus.jhu.edu/map.html. Accessed June 10, 2021.
[2] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054–62.
[3] Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol 2020;5:831–40.
[4] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–72.
[5] Lee YH, Bang ES, Lee JH, Lee JD, Kang DR, Hong J, et al. Serum concentrations of selenium status in critically ill patients according to severity stratification. Scand J Clin Lab Invest 2011;71:99–106.
[6] Lee SR. Critical role of zinc as either an antioxidant or a prooxidant in cellular systems. Oxid Med Cell Longev 2018;2018:9156285.
[7] Rech M, To L, Tovbin A, Smoot T, Mlynarek M. Heavy metal in the intensive care unit. Nutr Clin Pract 2014;29:78–89.
[8] Fonesch J, Alhazzani W, Blaser AR, Berger MM, Alhazzani W, Blaser AR, et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr 2019;38:48–79.
[9] Lichten LA, Cousins RJ. Mammalian zinc transporters: nutritional and physiologic regulation. Annu Rev Nutr 2009;29:153–76.
[10] Lee SR. Critical role of zinc as either an antioxidant or a prooxidant in cellular systems. Oxid Med Cell Longev 2018;2018:9156285.
[11] Heyland DK, Jones N, Cvijanovich NZ, King JC, Flori NR, Gildengorin G, Wong HR. Zinc homeostasis in pediatric critical illness. Pediatr Crit Care Med 2009;10:29–34.
[12] Alexandro J, Tinkov A, Strand TA, Alvehegan U, Skalne A, Aaseth J. Early nutritional interventions with zinc, selenium and vitamin D for raising anti-viral resistance against progressive COVID-19. Nutrients 2020;12:2358.
[13] Mossink JP. Zinc as nutritional intervention and prevention measure for COVID-19 disease. BMJ Nutr Prev Health 2020;3:111–7.
[14] Read SA, Obeid S, Ahlenstiel C, Ahlenstiel G. The role of zinc in antiviral immunity. Adv Nutr 2019;10:696–710.
[15] Zazzaque MS. COVID-19 pandemic: can zinc supplementation provide an additional shield against the infection? Comput Struct Biotechnol J 2021;19:1371–8.
[16] Kachur AV, Koch CJ, Biaglow JE. Mechanism of copper-catalyzed oxidation of glutathione. Free Radic Res 1998;28:259–69.
[17] Linko R, Karlsson S, Pettita V, Varpula T, Okkonen M, Lund V, et al. Serum zinc in critically ill adult patients with acute respiratory failure. Acta Anaesthesiol Scand 2011;55:615–21.
[18] Besecker BY, Eline MC, Hollyfield J, Phillips G, Disilvestro RW, Wewers MD, et al. A comparison of zinc metabolism, inflammation, and disease severity in critically ill infected and noninfected adults early after intensive care unit admission. Am J Clin Nutr 2011;93:1356–64.
[19] Elvira M, et al. Changes in zinc status and zinc transporters expression in whole blood of patients with Systemic Inflammatory Response Syndrome (SIRS). J Trace Elem Med Biol 2018;49:202–9.
[20] Alexander J, Tinkov A, Strand TA, Alvehegan U, Skalne A, Aaseth J. Early nutritional interventions with zinc, selenium and vitamin D for raising anti-viral resistance against progressive COVID-19. Nutrients 2020;12:2358.
[21] Hellman NE, Gilling JD. Ceruloplasmin metabolism and function. Annu Rev Nutr 2002;22:439–58.
[22] Berger MM, Baines M, Raffoul W, Benathan M, Chiolero RL, Reeves C, et al. Trace element supplementation after major burns modulates antioxidant status and clinical course by way of increased tissue trace element concentrations. Am J Clin Nutr 2007;85:1293–300.
[23] Berger MM, Binnert C, Chiolero RL, Taylor W, Raffoul W, Cuytsw MC, et al. Trace element supplementation after major burns increases burned skin trace element concentrations and modulates local protein metabolism but not whole-body substrate metabolism. Am J Clin Nutr 2007;85:1301–6.
[24] Besecker BY, Eline MC, Hollyfield J, Phillips G, Disilvestro RW, Wewers MD, et al. A comparison of zinc metabolism, inflammation, and disease severity in critically ill infected and noninfected adults early after intensive care unit admission. Am J Clin Nutr 2011;93:1356–64.
[25] Linko R, Karlsson S, Pettita V, Varpula T, Okkonen M, Lund V, et al. Serum zinc in critically ill adult patients with acute respiratory failure. Acta Anaesthesiol Scand 2011;55:615–21.
[26] Besecker BY, Eline MC, Hollyfield J, Phillips G, Disilvestro RW, Wewers MD, et al. A comparison of zinc metabolism, inflammation, and disease severity in critically ill infected and noninfected adults early after intensive care unit admission. Am J Clin Nutr 2011;93:1356–64.
[27] Linko R, Karlsson S, Pettita V, Varpula T, Okkonen M, Lund V, et al. Serum zinc in critically ill adult patients with acute respiratory failure. Acta Anaesthesiol Scand 2011;55:615–21.
[28] Besecker BY, Eline MC, Hollyfield J, Phillips G, Disilvestro RW, Wewers MD, et al. A comparison of zinc metabolism, inflammation, and disease severity in critically ill infected and noninfected adults early after intensive care unit admission. Am J Clin Nutr 2011;93:1356–64.
[29] Linko R, Karlsson S, Pettita V, Varpula T, Okkonen M, Lund V, et al. Serum zinc in critically ill adult patients with acute respiratory failure. Acta Anaesthesiol Scand 2011;55:615–21.
[30] Besecker BY, Eline MC, Hollyfield J, Phillips G, Disilvestro RW, Wewers MD, et al. A comparison of zinc metabolism, inflammation, and disease severity in critically ill infected and noninfected adults early after intensive care unit admission. Am J Clin Nutr 2011;93:1356–64.
[31] Linko R, Karlsson S, Pettita V, Varpula T, Okkonen M, Lund V, et al. Serum zinc in critically ill adult patients with acute respiratory failure. Acta Anaesthesiol Scand 2011;55:615–21.
[32] Besecker BY, Eline MC, Hollyfield J, Phillips G, Disilvestro RW, Wewers MD, et al. A comparison of zinc metabolism, inflammation, and disease severity in critically ill infected and noninfected adults early after intensive care unit admission. Am J Clin Nutr 2011;93:1356–64.
[33] Linko R, Karlsson S, Pettita V, Varpula T, Okkonen M, Lund V, et al. Serum zinc in critically ill adult patients with acute respiratory failure. Acta Anaesthesiol Scand 2011;55:615–21.
[34] Besecker BY, Eline MC, Hollyfield J, Phillips G, Disilvestro RW, Wewers MD, et al. A comparison of zinc metabolism, inflammation, and disease severity in critically ill infected and noninfected adults early after intensive care unit admission. Am J Clin Nutr 2011;93:1356–64.
[35] Linko R, Karlsson S, Pettita V, Varpula T, Okkonen M, Lund V, et al. Serum zinc in critically ill adult patients with acute respiratory failure. Acta Anaesthesiol Scand 2011;55:615–21.